Oxford Biomedica (OTCMKTS:OXBDF) – Investment analysts at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for Oxford Biomedica in a report issued on Friday. Jefferies Group analyst P. Welford anticipates that the company will earn $0.01 per share for the year.
Separately, ValuEngine cut shares of Oxford Biomedica from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd.
Oxford Biomedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.